134 related articles for article (PubMed ID: 28780998)
1. Risk factors for carbapenem-nonsusceptible Pseudomonas aeruginosa: Case-control study.
Khadem T; Stevens V; Holt K; Hoffmann C; Dumyati G; Brown J
Diagn Microbiol Infect Dis; 2017 Oct; 89(2):146-150. PubMed ID: 28780998
[TBL] [Abstract][Full Text] [Related]
2. Carbapenem-Nonsusceptible
Asempa TE; Nicolau DP; Kuti JL
J Clin Microbiol; 2019 Aug; 57(8):. PubMed ID: 31118271
[No Abstract] [Full Text] [Related]
3. Pseudomonas aeruginosa is not just in the intensive care unit any more: implications for empirical therapy.
Eagye KJ; Banevicius MA; Nicolau DP
Crit Care Med; 2012 Apr; 40(4):1329-32. PubMed ID: 22425824
[TBL] [Abstract][Full Text] [Related]
4. The quick loss of carbapenem susceptibility in Pseudomonas aeruginosa at intensive care units.
Zou Y; Lian J; Di Y; You H; Yao H; Liu J; Dong Y
Int J Clin Pharm; 2018 Feb; 40(1):175-182. PubMed ID: 29134489
[TBL] [Abstract][Full Text] [Related]
5. Characterization of Pseudomonas aeruginosa isolates from patients with urinary tract infections during antibiotic therapy.
Horii T; Muramatsu H; Morita M; Maekawa M
Microb Drug Resist; 2003; 9(2):223-9. PubMed ID: 12820809
[TBL] [Abstract][Full Text] [Related]
6. Effects of carbapenem exposure on the risk for digestive tract carriage of intensive care unit-endemic carbapenem-resistant Pseudomonas aeruginosa strains in critically ill patients.
Peña C; Guzmán A; Suarez C; Dominguez MA; Tubau F; Pujol M; Gudiol F; Ariza J
Antimicrob Agents Chemother; 2007 Jun; 51(6):1967-71. PubMed ID: 17420207
[TBL] [Abstract][Full Text] [Related]
7. Emergence of carbapenem resistance in Pseudomonas aeruginosa isolates from a patient with cystic fibrosis in the absence of carbapenem therapy.
Wolter DJ; Acquazzino D; Goering RV; Sammut P; Khalaf N; Hanson ND
Clin Infect Dis; 2008 Jun; 46(12):e137-41. PubMed ID: 18462098
[TBL] [Abstract][Full Text] [Related]
8. Clinical prediction tool to identify patients with Pseudomonas aeruginosa respiratory tract infections at greatest risk for multidrug resistance.
Lodise TP; Miller CD; Graves J; Furuno JP; McGregor JC; Lomaestro B; Graffunder E; McNutt LA
Antimicrob Agents Chemother; 2007 Feb; 51(2):417-22. PubMed ID: 17158943
[TBL] [Abstract][Full Text] [Related]
9. Distribution of Pseudomonas-Derived Cephalosporinase and Metallo-β-Lactamases in Carbapenem-Resistant Pseudomonas aeruginosa Isolates from Korea.
Cho HH; Kwon GC; Kim S; Koo SH
J Microbiol Biotechnol; 2015 Jul; 25(7):1154-62. PubMed ID: 25907063
[TBL] [Abstract][Full Text] [Related]
10. Association of ertapenem and antipseudomonal carbapenem usage and carbapenem resistance in Pseudomonas aeruginosa among 12 hospitals in Queensland, Australia.
McDougall DA; Morton AP; Playford EG
J Antimicrob Chemother; 2013 Feb; 68(2):457-60. PubMed ID: 23027714
[TBL] [Abstract][Full Text] [Related]
11. Carbapenem nonsusceptibility with modified
Choudhury D; Talukdar AD; Choudhury MD; Maurya AP; Chanda DD; Chakravorty A; Bhattacharjee A
Indian J Med Microbiol; 2017; 35(1):137-139. PubMed ID: 28303836
[TBL] [Abstract][Full Text] [Related]
12. Multilocus sequence typing reveals genetic diversity of carbapenem- or ceftazidime-nonsusceptible Pseudomonas aeruginosa in China.
Ji J; Wang J; Zhou Z; Wang H; Jiang Y; Yu Y
Antimicrob Agents Chemother; 2013 Nov; 57(11):5697-700. PubMed ID: 23939886
[TBL] [Abstract][Full Text] [Related]
13. Risk factors for healthcare-associated infection caused by carbapenem-resistant Pseudomonas aeruginosa.
Tsao LH; Hsin CY; Liu HY; Chuang HC; Chen LY; Lee YJ
J Microbiol Immunol Infect; 2018 Jun; 51(3):359-366. PubMed ID: 28988663
[TBL] [Abstract][Full Text] [Related]
14. Carbapenem-resistant Pseudomonas aeruginosa in Taiwan: Prevalence, risk factors, and impact on outcome of infections.
Lin KY; Lauderdale TL; Wang JT; Chang SC
J Microbiol Immunol Infect; 2016 Feb; 49(1):52-9. PubMed ID: 24662016
[TBL] [Abstract][Full Text] [Related]
15. Identification of patients with Pseudomonas aeruginosa respiratory tract infections at greatest risk of infection with carbapenem-resistant isolates.
Lodise TP; Miller C; Patel N; Graves J; McNutt LA
Infect Control Hosp Epidemiol; 2007 Aug; 28(8):959-65. PubMed ID: 17620244
[TBL] [Abstract][Full Text] [Related]
16. Risk factors for carbapenem-resistant Pseudomonas aeruginosa infection in a tertiary care hospital in Serbia.
Djordjevic Z; Folic M; Ruzic Zecevic D; Ilic G; Jankovic S
J Infect Dev Ctries; 2013 Sep; 7(9):686-90. PubMed ID: 24042106
[No Abstract] [Full Text] [Related]
17. [Carbapenem resistance in Pseudomonas aeruginosa isolated from urine cultures: prevalence and risk factors].
Álvarez-Otero J; Lamas-Ferreiro JL; González-González L; Rodríguez-Conde I; Fernández-Soneira MJ; Arca-Blanco A; Bermúdez-Sanjurjo JR; de la Fuente-Aguado J
Rev Esp Quimioter; 2017 Jun; 30(3):183-194. PubMed ID: 28440605
[TBL] [Abstract][Full Text] [Related]
18. High-Risk International Clones of Carbapenem-Nonsusceptible Pseudomonas aeruginosa Endemic to Indonesian Intensive Care Units: Impact of a Multifaceted Infection Control Intervention Analyzed at the Genomic Level.
Pelegrin AC; Saharman YR; Griffon A; Palmieri M; Mirande C; Karuniawati A; Sedono R; Aditianingsih D; Goessens WHF; van Belkum A; Verbrugh HA; Klaassen CHW; Severin JA
mBio; 2019 Nov; 10(6):. PubMed ID: 31719179
[TBL] [Abstract][Full Text] [Related]
19. Outbreak of carbapenem-resistant Pseudomonas aeruginosa infection in a surgical intensive care unit.
Kohlenberg A; Weitzel-Kage D; van der Linden P; Sohr D; Vögeler S; Kola A; Halle E; Rüden H; Weist K
J Hosp Infect; 2010 Apr; 74(4):350-7. PubMed ID: 20170982
[TBL] [Abstract][Full Text] [Related]
20. Influence of carbapenem resistance on mortality and the dynamics of mortality in Pseudomonas aeruginosa bloodstream infection.
Suárez C; Peña C; Gavaldà L; Tubau F; Manzur A; Dominguez MA; Pujol M; Gudiol F; Ariza J
Int J Infect Dis; 2010 Sep; 14 Suppl 3():e73-8. PubMed ID: 20223693
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
